Form 4: Tarsus Pharmaceuticals COO Reports Stock Transactions Following RSU Vesting

Tarsus Pharmaceuticals' Chief Operating Officer, Seshadri Neervannan, reports the acquisition of shares through RSU vesting and subsequent sale to cover tax obligations.

Summary

• Seshadri Neervannan, the Chief Operating Officer of Tarsus Pharmaceuticals, reported transactions involving the company's common stock.
• On March 15, 2024, Neervannan acquired 13,245 shares of common stock through the vesting of Restricted Stock Units (RSUs).
• Also on March 15, 2024, 5,097 RSUs granted on March 9, 2022, vested, and 8,148 RSUs granted on March 8, 2023, vested.
• On March 18, 2024, Neervannan sold 4,879 shares at a price of $30.60 per share.
• The sale was mandated by the Issuer's election to cover tax withholding obligations related to the vesting of RSUs.
• Following these transactions, Neervannan beneficially owns 64,767 shares of Tarsus Pharmaceuticals common stock and 34,638 Restricted Stock Units.

Sentiment

Score: 6

Explanation: Neutral sentiment as the transactions are routine and related to executive compensation and tax obligations. The sale is not necessarily indicative of a negative outlook.

Positives

• The vesting of RSUs indicates that the executive is meeting the continuous service requirements of the stock plan.

Negatives

• The sale of shares, even if for tax obligations, could be perceived negatively by some investors, although it is a common practice.

Risks

• Executive stock sales, even for tax purposes, can sometimes create short-term price volatility.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies. Monitoring these transactions can provide insights into management's perspective on the company's performance and future prospects. However, sales to cover tax obligations are generally viewed as routine and less indicative of management sentiment.

Comparison to Industry Standards

• Executive compensation packages often include RSUs that vest over time, aligning executive interests with long-term shareholder value.
• Companies like Amgen, Biogen, and Gilead Sciences also use RSUs as part of their executive compensation, with similar vesting schedules.
• The 'sell to cover' practice for tax obligations is a standard procedure among publicly traded companies to simplify tax management for employees.

Stakeholder Impact

• The transactions have a minimal direct impact on stakeholders, as they are related to executive compensation and tax obligations.
• The sale of shares could slightly increase the stock's trading volume.

Key Dates